Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 8, 2012

View Archived Issues

Intellect Neurosciences and iNovacia enter research service agreement

Circassia begins phase III ToleroMune trial in cat allergy

Empagliflozin has beneficial effects on blood pressure

U.S. Navy to investigate Oxygen Biotherapeutics' Oxycyte wound therapy

Updated study results on orteronel in prostate cancer presented

Preclinical profile of the prostate cancer vaccine candidate AEZS-120

Mirabegron safe in male patients with bladder outlet obstruction

Patient recruitment completed in two phase III Afrezza trials

Deciphera Pharmaceuticals announces transition to oncology drug development

National Institute of Biomedical Innovation patents new antibodies for cancer

Allergan presents new FPRL1 receptor ligands

Novel agents for diabetes prepared by Danish group

Industrial Research and University of Liverpool disclose novel BACE1 inhibitors

Locus Pharmaceuticals patents new ITK inhibitors

Researchers in Thailand synthesize novel dihydrofolate reductase inhibitors

DVS-603 improves psoriasis symptoms

Takeda aims to expand vaccine pipeline with acquisition

Chugai files application for approval of Avastin in additional indication in Japan

XenoPort discloses encouraging results from phase I trial of fumaric acid ester compound

MAA for ceftobiprole in pneumonia accepted for review under E.U. decentralized procedure

NICE publishes new draft guidance on ranibizumab for DME

The Medicines Company voluntarily discontinues development of MDCO-2010

Cempra reports topline results from phase II trial in urogenital gonorrhea

EMA accepts masitinib MAA for review

Zeria discontinues development of product candidate for allergic rhinitis

4-Antibody receives additional milestone payments from HGS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Neuro deals aplenty: UCB’s $1B+ takeover of Neurona the latest
BioWorld
A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything...
Pleased to own ya, Kelonia: Lilly’s $7B CAR T deal
BioWorld
The already-thriving CAR T space took another big stride forward as Eli Lilly and Co. disclosed its plan to acquire Boston-based Kelonia Therapeutics Inc. for as...